DVL1 and cancer: These results indicate that tumor suppressor p53 provides an important context of antagonistic interaction between nuclear YAP and the canonical Wnt pathway, and that the loss-of p53 in human cancer relieves the YAP restriction allowing co-activation of those oncogenic pathways by DVL.